LABORATORIO FARMACEUTICO ERFO S.P.A. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.125 EUR | -0.44% |
|
-1.32% | -14.12% |
| 03-29 | Laboratorio Farmaceutico Erfo, revenues grow and profit remains stable | AN |
| 02-19 | Mib in the red at 31,600; TIM still on top | AN |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 18.27 | 10.17 | 10.17 | - |
| Enterprise Value (EV) 1 | 17.27 | 8.57 | 8.17 | 7.67 |
| P/E ratio | - | 12.6 x | 18.8 x | 16.1 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 3.63 x | 1.61 x | 1.56 x | 1.37 x |
| EV / Revenue | 3.43 x | 1.36 x | 1.26 x | 1.04 x |
| EV / EBITDA | 9.58 x | 4.76 x | 5.11 x | 4.26 x |
| EV / FCF | -41.5 x | 8.57 x | 9.08 x | 6.97 x |
| FCF Yield | -2.41% | 11.7% | 11% | 14.3% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 9,000 | 9,000 | 9,000 | - |
| Reference price 2 | 2.030 | 1.130 | 1.130 | 1.130 |
| Announcement Date | 23-03-31 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | 5.104 | 5.028 | 6.3 | 6.5 | 7.4 |
| EBITDA 1 | - | 1.804 | 1.8 | 1.6 | 1.8 |
| EBIT 1 | - | 1.17 | 1.1 | 0.8 | 0.9 |
| Operating Margin | - | 23.26% | 17.46% | 12.31% | 12.16% |
| Earnings before Tax (EBT) 1 | - | 0.9485 | 1.1 | 0.8 | 0.9 |
| Net income 1 | 1.158 | 0.7161 | 0.8 | 0.6 | 0.7 |
| Net margin | 22.68% | 14.24% | 12.7% | 9.23% | 9.46% |
| EPS 2 | - | - | 0.0900 | 0.0600 | 0.0700 |
| Free Cash Flow 1 | - | -0.4161 | 1 | 0.9 | 1.1 |
| FCF margin | - | -8.27% | 15.87% | 13.85% | 14.86% |
| FCF Conversion (EBITDA) | - | - | 55.56% | 56.25% | 61.11% |
| FCF Conversion (Net income) | - | - | 125% | 150% | 157.14% |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 22-04-05 | 23-03-31 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 1 | 1.6 | 2 | 2.5 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -0.42 | 1 | 0.9 | 1.1 |
| ROE (net income / shareholders' equity) | - | 11.4% | 10.2% | 7.1% | 8.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 1.18 | 1.5 | 0.6 | 0.6 |
| Capex / Sales | - | 23.42% | 23.81% | 9.23% | 8.11% |
| Announcement Date | 22-04-05 | 23-03-31 | - | - | - |
1EUR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.13
EUR
Average target price
1.47
EUR
Spread / Average Target
+30.09%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.12% | 10.96M | |
| +33.09% | 700B | |
| -4.81% | 358B | |
| +19.05% | 330B | |
| +3.74% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +5.37% | 161B | |
| -2.10% | 157B |
- Stock Market
- Equities
- ERFO Stock
- Financials Laboratorio Farmaceutico Erfo S.p.A.